Lublin F, Miller DH, Freedman MS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016; 387: 1075–84—In this Article, the list of principal investigators in the appendix has been updated. This correction has been made to the online version as of Jan 19, 2017.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2jEPv6S
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Pulmonary complications post hematopoietic stem cell transplant in dyskeratosis congenita: analysis of oxidative stress in lung fibrobl...
-
Predictive Success Factors in Selective Upper Airway Stimulation. ORL J Otorhinolaryngol Relat Spec. 2017 Feb 24;79(1-2):121-128 Auth...
-
Abstract Background The introduction of aggressive chemo-radiotherapy regimens has improved overall survival in children with primitive ...
-
Background. Antitumor necrosis factor (anti-TNF) therapy is a highly effective but costly treatment for inflammatory bowel disease (IBD). Me...
-
Abstract Nonmotor symptoms (NMS) have been described in several neurodegenerative diseases but have not been systematically evaluated in sp...
-
Elementary school kids, on the other hand, can read, write, reason and think highly complex thoughts. Adele Faber and Elaine Mazlish, author...
-
by Mindaugas Paužuolis, Torsten Eich, Joachim Burman Background Natalizumab (NTZ) is a drug that has been widely used in the treatment of m...
-
by Jun Xu, Shuqing Chen, Baosheng Zeng, Anthony A. James, Anjiang Tan, Yongping Huang Manipulation of sex determination pathways in insect...
-
Abstract Purpose To develop the first photoactive biomaterial coating capable of controlled drug dosing via inclusion of synthesised drug-...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου